Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 18, 2025
Transactions
16
Purchases
0
Sales
16
Purchase value
$0.00
Sale value
$2.96M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Dominic PiscitelliChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Oct 21, 2026Period of report Oct 20, 20260001695028-26-000012
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 20, 2026
Common StockF1F2
14,000
$13.5279
$189.39K
69,828
Direct
Filing footnotes · 2
F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
F2Represents the weighted average share price of an aggregate total of 14,000 shares sold in the price range of $13.50 to $13.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Filed Oct 2, 2026Period of report Oct 1, 20260001584759-26-000017
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 1, 2026
Common StockF1F2
3,500
$12.9141
$45.20K
38,300
Direct
SaleOct 1, 2026
Common StockF1F2F3
3,200
$12.9141
$41.33K
203,472
IndirectSee footnote
Filing footnotes · 4
F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
F2This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
F4The shares subject to the option are fully vested and immediately exercisable.
Filed Sep 29, 2026Period of report Sep 28, 20260001695028-26-000010
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 28, 2026
Common StockF1F2
13,400
$13.5267
$181.26K
69,828
Direct
Filing footnotes · 2
F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
F2Represents the weighted average share price of an aggregate total of 13,400 shares sold in the price range of $13.50 to $13.575 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Filed Aug 28, 2026Period of report Aug 26, 20260001695028-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 26, 2026
Common StockF2
77,000
$13.6859
$1.05M
69,828
Direct
Filing footnotes · 3
F1Includes 1,680 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
F2The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
F325% of the shares subject to the option vested on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
Filed Feb 26, 2026Period of report Feb 24, 20260001695028-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleFeb 24, 2026
Common StockF1F2
52,000
$13.5132
$702.69K
68,148
Direct
Filing footnotes · 2
F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025.
F2Represents the weighted average share price of an aggregate total of 52,000 shares sold in the price range of $13.50 to $13.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Filed Jan 20, 2026Period of report Jan 16, 20260001584759-26-000006
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJan 16, 2026
Common StockF1F2
3,500
$12.0046
$42.02K
41,800
Direct
SaleJan 16, 2026
Common StockF1F2F3
3,200
$12.0046
$38.41K
213,072
IndirectSee footnote
Filing footnotes · 3
F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
F2Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
Filed Dec 17, 2025Period of report Dec 15, 20250001695028-25-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 16, 2025
Common StockF3F4
10,720
$9.0604
$97.13K
68,148
Direct
Filing footnotes · 7
F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
F2Includes 1,218 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
F3Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
F4Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0396 to $9.1953 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F51/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
F61/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
F71/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.
Filed Dec 17, 2025Period of report Dec 15, 20250001608936-25-000014
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 16, 2025
Common StockF2F3
33,374
$9.06
$302.37K
581,711
Direct
Filing footnotes · 6
F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
F2Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
F3Represents the weighted average share price of an aggregate total of 33,374 shares sold in the price range of $9.0257 to $9.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F41/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
F51/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
F61/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.
Filed Dec 17, 2025Period of report Dec 15, 20250001586894-25-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 16, 2025
Common StockF3F4
10,720
$9.0605
$97.13K
68,149
Direct
Filing footnotes · 7
F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
F2Includes an aggregate of 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
F3Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
F4Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0449 to $9.1451 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F51/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
F61/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
F71/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.